Eli Lilly


Zuellig Pharma
Concise Prescribing Info
Monotherapy or in combination w/ paclitaxel for adult patients w/ advanced gastric cancer or gastro-oesophageal junction (GEJ) adenocarcinoma w/ disease progression after prior platinum & fluoropyrimidine chemotherapy. In combination w/ irinotecan, folinic acid & 5-fluorouracil (FOLFIRI) for adult patients w/ metastatic colorectal cancer (mCRC) w/ disease progression on or after prior therapy w/ bevacizumab, oxaliplatin & fluoropyrimidine. In combination w/ docetaxel for adult patients w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) w/ disease progression after platinum-based chemotherapy.
Dosage/Direction for Use
Gastric cancer & GEJ adenocarcinoma 8 mg/kg every 2 wk as single agent or in combination w/ paclitaxel: 8 mg/kg on days 1 & 15 of 28-day cycle, prior to paclitaxel 80 mg/m2 IV infusion over approx 60 min on days 1, 8 & 15 of 28-day cycle. Colorectal cancer 8 mg/kg IV infusion every 2 wk prior to FOLFIRI administration. NSCLC 10 mg/kg on day 1 of 21-day cycle, prior to docetaxel 75 mg/m2 IV infusion over approx 60 min on day 1 of 21-day cycle. East Asian patient Reduce docetaxel to 60 mg/m2 on day 1 of 21-day cycle.
Hypersensitivity. For NSCLC, tumour cavitation or tumour involvement of major vessels.
Special Precautions
Infusion-related reactions. Permanently discontinue in patients w/ severe arterial thromboembolic events, GI perforations, Grade 3 or 4 bleeding, urine protein level >3 g/24 hr or in the event of nephrotic syndrome. Increased incidence of severe HTN, impaired wound healing, fistula development, stomatitis. Na-restricted diet. May affect ability to drive & use machines. Severe liver cirrhosis, cirrhosis w/ hepatic encephalopathy, ascites due to cirrhosis or hepatorenal syndrome. Severe renal impairment. Women of childbearing potential should use effective contraception during & up to 3 mth after last dose. Not recommended during pregnancy. Discontinue during lactation. Elderly w/ NSCLC.
Adverse Reactions
Neutropenia, febrile neutropenia; leukopenia, thrombocytopenia; hypoalbuminaemia; HTN; epistaxis; GI haemorrhage events, stomatitis; proteinuria; fatigue/asthenia; peripheral oedema; abdominal pain, diarrhea; palmar-plantar erythrodysaesthesia syndrome; mucosal inflammation; hypokalaemia; hyponatraemia; headache.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XC21 - ramucirumab ; Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
Cyramza infusion conc 100 mg/10 mL
Cyramza infusion conc 500 mg/50 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in